Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Deborah Bartholdi is active.

Publication


Featured researches published by Deborah Bartholdi.


The Lancet | 2012

Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study

Anita Rauch; Dagmar Wieczorek; Elisabeth Graf; Thomas Wieland; Sabine Endele; Thomas Schwarzmayr; Beate Albrecht; Deborah Bartholdi; Jasmin Beygo; Nataliya Di Donato; Andreas Dufke; Kirsten Cremer; Maja Hempel; Denise Horn; Juliane Hoyer; Pascal Joset; Albrecht Röpke; Ute Moog; Angelika Riess; Christian Thiel; Andreas Tzschach; Antje Wiesener; Eva Wohlleber; Christiane Zweier; Arif B. Ekici; Alexander M. Zink; Andreas Rump; Christa Meisinger; Harald Grallert; Heinrich Sticht

BACKGROUND The genetic cause of intellectual disability in most patients is unclear because of the absence of morphological clues, information about the position of such genes, and suitable screening methods. Our aim was to identify de-novo variants in individuals with sporadic non-syndromic intellectual disability. METHODS In this study, we enrolled children with intellectual disability and their parents from ten centres in Germany and Switzerland. We compared exome sequences between patients and their parents to identify de-novo variants. 20 children and their parents from the KORA Augsburg Diabetes Family Study were investigated as controls. FINDINGS We enrolled 51 participants from the German Mental Retardation Network. 45 (88%) participants in the case group and 14 (70%) in the control group had de-novo variants. We identified 87 de-novo variants in the case group, with an exomic mutation rate of 1·71 per individual per generation. In the control group we identified 24 de-novo variants, which is 1·2 events per individual per generation. More participants in the case group had loss-of-function variants than in the control group (20/51 vs 2/20; p=0·022), suggesting their contribution to disease development. 16 patients carried de-novo variants in known intellectual disability genes with three recurrently mutated genes (STXBP1, SYNGAP1, and SCN2A). We deemed at least six loss-of-function mutations in six novel genes to be disease causing. We also identified several missense alterations with potential pathogenicity. INTERPRETATION After exclusion of copy-number variants, de-novo point mutations and small indels are associated with severe, sporadic non-syndromic intellectual disability, accounting for 45-55% of patients with high locus heterogeneity. Autosomal recessive inheritance seems to contribute little in the outbred population investigated. The large number of de-novo variants in known intellectual disability genes is only partially attributable to known non-specific phenotypes. Several patients did not meet the expected syndromic manifestation, suggesting a strong bias in present clinical syndrome descriptions. FUNDING German Ministry of Education and Research, European Commission 7th Framework Program, and Swiss National Science Foundation.


European Journal of Neuroscience | 1997

Expression of Pro‐Inflammatory Cytokine and Chemokine mRNA Upon Experimental Spinal Cord Injury in Mouse: an In Situ Hybridization Study

Deborah Bartholdi; Martin E. Schwab

Injury to the spinal cord induces a complex cascade of cellular reactions at the local lesion area: secondary cell death and inflammatory reactions as well as scar and cavity formation take place. In order to investigate the molecular features underlying this local wounding response and to determine their pathophysiological implications, we studied the expression pattern of pro‐inflammatory and chemoattractant cytokines in an experimental spinal cord injury model in mouse. We show by in situ hybridization that transcripts for the pro‐inflammatory cytokines TNFα and IL‐1 as well as the chemokines MIP‐1 α and MIP‐1β are upregulated within the first hour following injury. In this early phase, the expression of the pro‐inflammatory cytokines is restricted to cells in the surroundings of the lesion area probably resident CNS cells. While TNFα is expressed in a very narrow time window, IL‐1 can be detected in a second phase in a subset of polymorphonuclear granulocytes which immigrate into the spinal cord around 6 h. Message for the chemokines MIP‐1α and β is expressed in a generalized way in the grey matter of the entire spinal cord around 24 h and gets again restricted to the cellular infiltrate at the lesion site at 4 days following injury. Interestingly, our data suggest that resident CNS cells, most probably microglial cells, and not peripheral inflammatory cells, are the main source for cytokine and chemokine mRNAs. The defined cytokine pattern observed indicates that the inflammatory events upon lesioning the CNS are tightly controlled. The very early expression of pro‐inflammatory cytokine and chemokine messages may represent an important element of the recruitment of inflammatory cells. Additional pathophysiological consequences of the specific cytokine pattern observed remain to be determined.


American Journal of Human Genetics | 2005

Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease

Jeroen H. Roelfsema; Stefan J. White; Yavuz Ariyurek; Deborah Bartholdi; Dunja Niedrist; Francesco Papadia; Carlos A. Bacino; Johan T. den Dunnen; Gert-Jan B. van Ommen; Martijn H. Breuning; Raoul C. M. Hennekam; Dorien J.M. Peters

CREB-binding protein and p300 function as transcriptional coactivators in the regulation of gene expression through various signal-transduction pathways. Both are potent histone acetyl transferases. A certain level of CREB-binding protein is essential for normal development, since inactivation of one allele causes Rubinstein-Taybi syndrome (RSTS). There is a direct link between loss of acetyl transferase activity and RSTS, which indicates that the disorder is caused by aberrant chromatin regulation. We screened the entire CREB-binding protein gene (CBP) for mutations in patients with RSTS by using methods that find point mutations and larger rearrangements. In 92 patients, we were able to identify a total of 36 mutations in CBP. By using multiple ligation-dependent probe amplification, we found not only several deletions but also the first reported intragenic duplication in a patient with RSTS. We extended the search for mutations to the EP300 gene and showed that mutations in EP300 also cause this disorder. These are the first mutations identified in EP300 for a congenital disorder.


Nature Genetics | 2009

Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair

Viviana Cordeddu; Elia Di Schiavi; Len A. Pennacchio; Avi Ma'ayan; Anna Sarkozy; Valentina Fodale; Serena Cecchetti; Alessio Cardinale; Joel Martin; Wendy Schackwitz; Anna Lipzen; Giuseppe Zampino; Laura Mazzanti; Maria Cristina Digilio; Simone Martinelli; Elisabetta Flex; Francesca Lepri; Deborah Bartholdi; Kerstin Kutsche; Giovanni Battista Ferrero; Cecilia Anichini; Angelo Selicorni; Cesare Rossi; Romano Tenconi; Martin Zenker; Daniela Merlo; Bruno Dallapiccola; Ravi Iyengar; Paolo Bazzicalupo; Bruce D. Gelb

N-myristoylation is a common form of co-translational protein fatty acylation resulting from the attachment of myristate to a required N-terminal glycine residue. We show that aberrantly acquired N-myristoylation of SHOC2, a leucine-rich repeat–containing protein that positively modulates RAS-MAPK signal flow, underlies a clinically distinctive condition of the neuro-cardio-facial-cutaneous disorders family. Twenty-five subjects with a relatively consistent phenotype previously termed Noonan-like syndrome with loose anagen hair (MIM607721) shared the 4A>G missense change in SHOC2 (producing an S2G amino acid substitution) that introduces an N-myristoylation site, resulting in aberrant targeting of SHOC2 to the plasma membrane and impaired translocation to the nucleus upon growth factor stimulation. Expression of SHOC2S2G in vitro enhanced MAPK activation in a cell type–specific fashion. Induction of SHOC2S2G in Caenorhabditis elegans engendered protruding vulva, a neomorphic phenotype previously associated with aberrant signaling. These results document the first example of an acquired N-terminal lipid modification of a protein causing human disease.


Brain Research | 1995

Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat

Deborah Bartholdi; Martin E. Schwab

Experimental studies and clinical observations show that spinal cord lesions are greatly enlarged by a process called secondary cell death. A detailed understanding of the molecular and cellular processes underlying these events is still lacking. In clinical studies using methylprednisolone in spinal cord injured patients a mega-dose of methylprednisolone applied during the first few hours after injury was found to improve the neurological outcome. In the present study the possible neuroprotective mechanism of methylprednisolone was assessed by histologically studying its effect on the extent of secondary cell death and on early inflammatory reactions following partial transection of the spinal cord in the rat. Our results show that a single high dose of 30 or 60 mg/kg methylprednisolone affects neither the time course nor the extent of secondary cell death. In contrast, methylprednisolone markedly suppressed the invasion of the injured spinal cord tissue by polymorphonuclear granulocytes and macrophages. The role of these inflammatory cells in traumatic CNS lesions is very unclear at present. It is possible that they lead to further damage of the injured spinal cord tissue and that the beneficial effect of methylprednisolone is at least partially due to its anti-inflammatory effect, thereby inhibiting bystander damage of invading inflammatory cells.


Nature Genetics | 2011

De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome

Alexander Hoischen; Bregje W.M. van Bon; Benjamín Rodríguez-Santiago; Christian Gilissen; Lisenka E.L.M. Vissers; Petra de Vries; Irene M. Janssen; Bart van Lier; Rob Hastings; Sarah F. Smithson; Ruth Newbury-Ecob; Susanne Kjaergaard; Judith A. Goodship; Ruth McGowan; Deborah Bartholdi; Anita Rauch; Maarit Peippo; Jan M Cobben; Dagmar Wieczorek; Gabriele Gillessen-Kaesbach; Joris A. Veltman; Han G. Brunner; Bert B.A. de Vries

Bohring-Opitz syndrome is characterized by severe intellectual disability, distinctive facial features and multiple congenital malformations. We sequenced the exomes of three individuals with Bohring-Opitz syndrome and in each identified heterozygous de novo nonsense mutations in ASXL1, which is required for maintenance of both activation and silencing of Hox genes. In total, 7 out of 13 subjects with a Bohring-Opitz phenotype had de novo ASXL1 mutations, suggesting that the syndrome is genetically heterogeneous.


Journal of Medical Genetics | 2008

Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell Syndrome (SRS): Results from a large cohort of patients with SRS and SRS-like phenotypes.

Deborah Bartholdi; Małgorzata Krajewska-Walasek; Katrin Õunap; Harald Gaspar; Krystyna H. Chrzanowska; Helena Ilyana; Hülya Kayserili; Iosif W. Lurie; Albert Schinzel; Alessandra Baumer

Background: Silver–Russell syndrome (SRS) is a clinically and genetically heterogeneous condition characterised by severe intrauterine and postnatal growth retardation. Loss of DNA methylation at the telomeric imprinting control region 1 (ICR1) on 11p15 is an important cause of SRS. Methods: We studied the methylation pattern at the H19-IGF2 locus in 201 patients with suspected SRS. In an attempt to categorise the patients into different subgroups, we developed a simple clinical scoring system with respect to readily and unambiguously assessable clinical features. In a second step, the relationship between clinical score and epigenetic status was analysed. Results and conclusions: The scoring system emerged as a powerful tool for identifying those patients with both a definite SRS phenotype and carrying an epimutation at 11p15. 53% of the 201 patients initially enrolled fulfilled the criteria for SRS and about 40% of them exhibited an epimutation at the H19-IGF2 locus. Methylation defects were restricted to patients who fulfilled the diagnostic criteria for SRS. Patients carrying epimutations had a more severe phenotype than either the SRS patients with mUPD7 or the idiopathic SRS patients. The majority of patients with methylation abnormalities showed hypomethylation at both the H19 and IGF2 genes. However, we also identified SRS patients where hypomethylation was restricted to either the H19 or the IGF2 gene. Interestingly, we detected epimutations in siblings of normal parents, most likely reflecting germ cell mosaicism in the fathers. In one family, we identified an epimutation in an affected father and his likewise affected daughter.


Annals of Neurology | 2014

GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy.

Johannes R. Lemke; Rik Hendrickx; Kirsten Geider; Bodo Laube; Michael Schwake; Robert J. Harvey; Victoria M. James; Alex Pepler; Isabelle Steiner; Konstanze Hörtnagel; John Neidhardt; Susanne Ruf; Markus Wolff; Deborah Bartholdi; Roberto Horacio Caraballo; Konrad Platzer; Arvid Suls; Saskia Biskup; Sarah Weckhuysen

To identify novel epilepsy genes using a panel approach and describe the functional consequences of mutations.


European Journal of Neuroscience | 1997

VEGF mRNA Induction Correlates With Changes in the Vascular Architecture Upon Spinal Cord Damage in the Rat

Deborah Bartholdi; Beatrix P. Rubin; Martin E. Schwab

The multiple cellular and molecular processes induced by injury to the central nervous system (CNS) are still poorly understood. In the present study, we investigated the response of the vasculature and the expression of mRNA for the angiogenic vascular endothelial growth factor (VEGF) following X‐irradiation of the spinal cord in the newborn and following traumatic spinal cord injury in the adult rat. Both lesion models induced changes in the density and the distribution pattern of blood vessels: while X‐irradiation led to a permanent local increase in vascular density in the fibre tracts of the exposed segments, a transient local sprouting of vessels was induced upon traumatic spinal cord injury. In situ hybridization showed that an increase of VEGF mRNA anticipated and overlapped with the vascular responses in both lesion models. In addition to the temporal correlation of VEGF expression and vascular sprouting, there was a clear correlation in the spatial distribution patterns. Following X‐irradiation, the expression of VEGF mRNA was restricted to the fibre tracts, precisely the areas where the changes in the vasculature were observed later on. Upon transection in the adult animal, VEGF was mainly detectable at the border of the lesion area, where the transient increase in vascular density could be observed. Interestingly, according to the type of lesion applied, astrocytes (X‐irradiation) or inflammatory cells (presumably microglial cells or macrophages; traumatic lesion) are the cellular sources of VEGF mRNA. Our results strongly indicate that VEGF is crucially involved in mediating vascular changes following different types of injury in the CNS.


Journal of Medical Genetics | 2007

Genetic heterogeneity in Rubinstein–Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300

Deborah Bartholdi; Jeroen H. Roelfsema; Francesco Papadia; Martijn H. Breuning; Dunja Niedrist; Raoul C. M. Hennekam; Albert Schinzel; Dorien J.M. Peters

Background: Rubinstein–Taybi syndrome (RSTS) is a congenital disorder characterised by growth retardation, facial dysmorphisms, skeletal abnormalities and mental retardation. Broad thumbs and halluces are the hallmarks of the syndrome. RSTS is associated with chromosomal rearrangements and mutations in the CREB-binding protein gene (CREBBP), also termed CBP, encoding the CREB-binding protein. Recently, it was shown that mutations in EP300, coding for the p300 protein, also cause RSTS. CBP and EP300 are highly homologous genes, which play important roles as global transcriptional coactivators. Objective: To report the phenotype of the presently known patients with RSTS (n = 4) carrying germline mutations of EP300. Results: The patients with EP300 mutations displayed the typical facial gestalt and malformation pattern compatible with the diagnosis of RSTS. However, three patients exhibited much milder skeletal findings on the hands and feet than typically observed in patients with RSTS. Conclusions: Part of the clinical variability in RSTS is explained by genetic heterogeneity. The diagnosis of RSTS must be expanded to include patients without broad thumbs or halluces.

Collaboration


Dive into the Deborah Bartholdi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eugen Boltshauser

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge